Analysis of Treatment Option for Synchronous Liver Metastases and Colon Rectal Cancer

Abstract

Colorectal or bowel cancer is one of the major causes of cancer worldwide. Research has shown that 15 to 20% colorectal cancer patients are also diagnosed with synchronous liver metastases (LM) at presentation and about one third eventually develop liver lesions (Leporrier, Maurel, Chiche, Bara, Segol, and Launoy, 2006; Manfredi, Lepage, Hatem, Coatmeur, Faivre, and Bouvier, 2006).   Management of cases with colorectal cancer comorbid with liver metastases is more complex (Schmoll, Van Cutsem, Stein, Valentini, Glimelius, Haustermans et al., 2012; Bismuth, Castaing, and Traynor, 1988). This highlights the need for suggesting the need for effective treatment while optimizing timing during surgical and medical treatment of primary plus metastatic disease. According to Fong, Fortner, Sun, Brennan, and Blumgart, 1999), such patients cases are likely to present with severe cancer biology and thereby less likely to be long-term survivors.